P/E ratio for Acorda Therapeutics (ACOR)
P/E ratio as of May 2024 (TTM): -0.0676
According to Acorda Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0676042. At the end of 2022 the company had a P/E ratio of -0.0087.
P/E ratio history for Acorda Therapeutics from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0087 | -27.09% |
| 2021 | -0.0120 | -31.16% |
| 2020 | -0.0174 | -1.94% |
| 2019 | -0.0177 | -101.64% |
| 2018 | 1.08 | -588.26% |
| 2017 | -0.2216 | -82.08% |
| 2016 | -1.24 | -115.03% |
| 2015 | 8.23 | 73.11% |
| 2014 | 4.75 | 33.46% |
| 2013 | 3.56 | 1023.01% |
| 2012 | 0.3171 | -79.52% |
| 2011 | 1.55 | -137.48% |
| 2010 | -4.13 | 627.72% |
| 2009 | -0.5676 | 21.21% |
| 2008 | -0.4683 | -38.16% |
| 2007 | -0.7572 | 336.94% |
| 2006 | -0.1733 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | -16.9 | 24,893.42% | 🇺🇸 USA |
 Repligen
RGEN | 78.9 | -116,800.89% | 🇺🇸 USA |
 Affimed
AFMD | -6.63 | 9,700.83% | 🇩🇪 Germany |
 BioMarin Pharmaceutical BMRN | 105 | -155,340.35% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.